Navigation Links
Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril

tigators.

When these data were examined to determine the blood pressure goal endpoint, more patients treated with the BENICAR HCT study doses reached blood pressure goals recommended by JNC 7 (<140/90 mm Hg and <130/80 mm Hg) than those treated with the amlodipine + benazepril study doses(2). In patients receiving BENICAR HCT combination therapy (40/12.5-40/25 mg), 66 percent achieved a BP goal of <140/90 mm Hg and 33 percent achieved a BP goal of <130/80 mm Hg. In patients receiving amlodipine 5-10 mg + benazepril 20 mg, 45 percent achieved a BP goal of <140/90 mm Hg and 14 percent achieved a BP goal of <130/80 mm Hg.

In specifically examining the highest dose studied in both treatment arms, Dr. Punzi reported that 61 percent of the patients receiving BENICAR HCT 40/25 mg at week 12 reached a goal of BP<140/90 mm Hg, nearly 42 percent reached BP<130/85 mm Hg, and 30 percent reached BP<130/80 mm Hg, compared to 39 percent, 19 percent and 13 percent, respectively, of patients who were treated with amlodipine 10 mg + benazepril 20 mg.

Hypertension, also known as high blood pressure, affects approximately 72 million people in the United States and approximately one billion worldwide(3). Called the "silent killer" because it often has no specific symptoms, hypertension increases the risk of cardiovascular and related diseases such as stroke, heart attack, heart failure and kidney disease(4). Of those diagnosed with high blood pressure, 64.9 percent did not have the condition under control(5).

Study Design

The purpose of this study was to compare the blood pressure lowering effect of fixed dose combinations of BENICAR HCT with combinations of amlodipine + benazepril. Patients who failed to achieve the desired goal (<120/80 mm Hg) at any visit underwent dosage titration and were switched to combination therapy and titrated to the maximum available dose at the time of the study.

Patients were randomized to either 2 weeks of double-
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
3. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
4. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
5. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
6. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
7. Lipitor Provides Unprecedented Cardiovascular Risk Reductions in Diabetes Patients with Metabolic Syndrome and in Stroke Patients
8. Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies
9. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
10. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
11. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
Post Your Comments:
(Date:10/6/2008)...oncept of Other Product - Company,s Bioabsorbable ... HONG KONG, Oct. 6 /- Data from mult...ing stent, OrbusNeich,s Genous Bio-engineered R,st...ter Cardiovascular,Therapeutics symposium, TCT 200...Ph.D., of the Academic Medical Center in,Amsterdam...
(Date:10/3/2008)...IK, Iceland, Oct. 3 /- deCO...iling of an investigational new drug,(IND) applica... modulator,of phosphodiesterase 4 (PDE4), with the...nd is being developed as a new and potentially saf...nd cognitive deficits associated,with Alzheimer,s ...
(Date:10/2/2008)...October 2 /- Pharmaleads has obtained...horization to perform a single,ascending dose Phas...eatment of neuropathic pain., Neuropathic pain is...,prevalence in the world,s population of up to 6%,...auses such as shingles, herpes, diabetes,antivira...
(Date:10/2/2008)... England, October 2 /- Circassia Ltd,...the fields of allergy and critical,care, today ann...udy of its,ToleroMune(R) technology in the field o...s achieved in an earlier phase II study, which dem...oleroMune approach to allergy,desensitization., I...
Breaking Medicine Technology:Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 2deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 4deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 5Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I 2Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology 2Navitas Opens Cancer Rehabilitation Center in Denver in Conjunction With Presbyterian St Lukes Medical Center 7646 1Navitas Opens Cancer Rehabilitation Center in Denver in Conjunction With Presbyterian St Lukes Medical Center 7646 2Navitas Opens Cancer Rehabilitation Center in Denver in Conjunction With Presbyterian St Lukes Medical Center 7646 3New study finds biodiversity conservation secures ecosystem services for people 1471 1New study finds biodiversity conservation secures ecosystem services for people 1471 2Atomic bomb survivor scientists mark 60 years of long term radiation study 1470 1Atomic bomb survivor scientists mark 60 years of long term radiation study 1470 2CME LLC Restructures Announces Its New Executive Management Team 2074 1CME LLC Restructures Announces Its New Executive Management Team 2074 2
(Date:10/6/2008)...S, Ohio, Oct. 6 /PRNewswire/ -- Ohio,s academic he...e state,s economy in 2007, an,increase of approxim...jor,job generator, employing one in 12 Ohioans, ac... Council of Medical Deans., Quantifying academic ...ax revenue to job creation, the report underscores...
(Date:10/6/2008)... Millions of women suffer with sympt...-billion economic rescue plan. But the effects of ... to come making it increasingly difficult for U.S....tricia Beckstead announces new cost effective drug...f without a prescription. , ...
(Date:10/6/2008)...F, Germany, Oct. 6 /PRNewswire-FirstCall/ -- SAP A...a has joined SAP as senior vice president,of the H..., effective,August 1, 2008, Mr. Papandrea will hel...ding strategic software solutions to healthcare,or... made in conjunction,with the 3rd annual Ambassado...
(Date:10/5/2008)...A--A simple blood test may help detect serious bac...ions and blood stream infections in young infants ...ers that have no clear cause. Researchers at Child...ators at George Washington University, show that a...lp identify infants at high risk for SBIs while po...
Breaking Medicine News(10 mins):Health News:Academic Medicine Means Business for Ohio: $37.2 Billion Economic Impact for the State 2Health News:Menopause Relief: Award-Winning Physician Announces New Cost Effective Drug-Free Guidelines 2Health News:Menopause Relief: Award-Winning Physician Announces New Cost Effective Drug-Free Guidelines 3Health News:SAP Appoints John Papandrea to Lead Healthcare Business Unit 2Health News:SAP Appoints John Papandrea to Lead Healthcare Business Unit 3Health News:New test could help catch serious infections in babies 2
... fractures linked to osteoporosis without the need...ifornia have been looking at the effect of a new t...ients with osteoporosis. They injected an acrylic ...rly done during surgery. Two weeks later//, many p...
...ly detection of all forms of cancer has been devel...lesterol test, the 'C-Test' will be evaluated in a...hs. It is based on scientific work by the John Bas...t the Engalnd National University. Professor Rodri...
... of the potentially fatal condition pre-eclampsia ...The study, published in the Lancet, found that tak...g pre-eclampsia. The condition involves the pregn...can interfere with the feeding of the unborn child...
...echnology will provide the most effective defence ...genome project, and developments in understanding...in developing tests and vaccines that will protect...- as well as natural epidemics.// The annual meeti...
Other Medicine News:Health News:Detection of Cancer 2Health News:Biotechnology on the lead 2
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
Medicine Products: